Dr Robert Gabbay Discusses the Importance of New CKD Section in ADA Guidelines

Robert Gabbay, MD, PhD, of the American Diabetes Association, explains why a section on chronic kidney disease management was added to the ADA's 2022 standard of care guidelines.

Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), explains why a section on chronic kidney disease (CKD) management was added to the ADA's 2022 standard of care guidelines.

Transcript:

What evidence led to the addition of Section 11 in the ADA’s 2022 guidelines?

Gabbay: [A couple] of the things that became clear based on some of the recent studies and new treatments that are available are a couple of things. One, we know that chronic kidney disease continues to be a huge issue and it's under-diagnosed and under-treated. And second, we now have new treatments that can really lower the risk of chronic kidney disease, and particularly the progression. So, we called out all of that information by making chronic kidney disease a separate section [of the guidelines] to emphasize the importance of it.

Related Videos
Jeremy Wigginton, MD
Screenshot of Eva Parker, MD, smiling during an interview
Screenshot of Eleonora Lad, MD, PhD, smiling
Davey B. Daniel, MD, Chief Medical Officer, OneOncology
Debra Patt, MD, PhD, MBA, Executive Vice President, Texas Oncology
Michael Burger
Jeffrey Casberg
Amy Valley, Vice President for Clinical Strategy and Technology Solutions, Cardinal Health
Ben Jones, Vice President of Government Relations and Public Policy, US Oncology Network
Yuqian Liu, PharmD
Related Content
© 2023 MJH Life Sciences
AJMC®
All rights reserved.